Skip to content
montabiosciences.commontabiosciences.com
  • Home
  • About us
    • Company History
    • Management
    • Board of Directors
    • Founders
  • Technology
    • Todays Challenges
    • Cancer Treatment
    • Cancer Immunotherapy
    • Development
    • References
  • News
  • Contact us
MonTa Biosciences featured in Nature pharmadealmakers magazine
March 28, 2022

MonTa Biosciences was featured as an upcoming biotech oncology company in Natures edition of pharmadealmakers. [...]

MonTa Biosciences successfully dose first patient in phase I clinical trial
April 23, 2021

MonTa Biosciences this week successfully enrolled and dosed the first cancer patient in our phase [...]

MonTa Biosciences awarded approval from regulatory agencies to start phase I study
January 18, 2021

MonTa Biosciences was awarded with positive feedback from the regulatory agency in Denmark to initiate [...]

MonTa Biosciences becomes a Clinical Stage Company
November 19, 2020

MonTa Biosciences today announced that the company has transitioned from a preclinical to a Clinical [...]

MonTa Biosciences initiates collaboration with NCI under the Nanotechnology Characterization Laboratory program
September 8, 2020

MonTa Biosciences has successfully gone through a tough selection process and been enrolled into the [...]

MonTa Biosciences successfully completed regulatory advice meeting with the Danish Medicines Agency
August 8, 2020

MonTa Biosciences have completed our regulatory meeting with the Danish Medicines Agency to align views [...]

MonTa Biosciences recruits Chief Medical Officer Steven Glazer to bring MonTas lead candidate MBS8 into clinical development
April 30, 2020

Steven Glazer is a well renowned clinical expert and biotech entrepreneur who has a strong [...]

MonTa Biosciences close a Series A investment from existing investors to complete phase I in cancer patients
December 20, 2019

MonTa Biosciences announced completion of a Series A investment from existing investor Consolidated Biosciences Aps [...]

Selected as an alumni case in the Nordic Mentoring Programme

MonTa Biosceinces was selected among successful biotech startups in the Nordic Mentoring Programme as an [...]

02
Dec
Attending the BioEurope conference in Hamburg
November 1, 2019

MonTa Biosciences is attending the BioEurope conference in Hamburg to meet with biotech and pharma companies [...]

Presenting data at the cancer immunotherapy SITC conference
October 30, 2019

MonTa Biosciences is attending the cancer immunotherapy SITC conference in Washington DC to present data on our [...]

Meeting with Key Opinion Leaders to plan phase I trial in patients
September 29, 2019

MonTa Biosciences attends the ESMO conference in Barcelona to meet with Key Opinion Leaders to [...]

Fireside interview at the IP-FAIR conference
May 2, 2019

MonTa Biosciences is invited to a fireside interview at the IP-FAIR conference in Copenhagen on May 8. [...]

Pharma business conference BioEurope in Vienna
March 20, 2019

MonTa Biosciences join the pharma business conference BioEurope in Vienna to meet with pharma and biotech [...]

Investment with Consolidated Holdings
January 30, 2019

MonTa Biosciences closes investment with Consolidated Holdings to secure future development towards clinical trials. Link [...]

Invitation to speak and join panel discussion at the NLSDays
July 5, 2018

MonTa Biosciences is invited to speak and join panel discussion with major Big Pharma companies Roche [...]

MonTa Biosciences attend Bio in Boston
May 30, 2018

MonTa Biosciences attend Bio in Boston from June 4-7th to meet and discuss partnership, collaborations and investment opportunities. Send [...]

The AngloNordic Life science conference
May 10, 2018

MonTa Biosciences attend the AngloNordic Life science conference in London on Mya 24th to meet investors and network [...]

Attending the Biotechandmoney conference
January 5, 2018

MonTa Biosciences attend the Biotechandmoney conference in London on February 5-6. [...]

BioEurope partnering conference in Berlin
November 5, 2017

MonTa Biosciences attends the BioEurope partnering conference in Berlin from November 4-8. Please book a meeting with [...]

  • 1
  • 2

MonTa Biosciences ApS

Diplomvej 381
2800 Kgs. Lyngby
Denmark

VAT nr. 36697016




    By contacting us, you agree to our privacy statement.

    Privacy statement
    MonTa Biosciences - Cancer Therapeutics of Tomorrow
    • Home
    • About us
      • Company History
      • Management
      • Board of Directors
      • Founders
    • Technology
      • Todays Challenges
      • Cancer Treatment
      • Cancer Immunotherapy
      • Development
      • References
    • News
    • Contact us